Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock closed at 1.39 per share at the end of the most recent trading day (a 0.72% change compared to the prior day closing price) with a volume of 769.58K shares and market capitalization of 13.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. CEO is Spiro Rombotis.

The one-year performance of Cyclacel Pharmaceuticals Inc. stock is -78.93%, while year-to-date (YTD) performance is -64.27%. CYCC stock has a five-year performance of -98.3%. Its 52-week range is between 1.05 and 6.64, which gives CYCC stock a 52-week price range ratio of 6.08%

Cyclacel Pharmaceuticals Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 0.36, a price-to-sale (PS) ratio of 88.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.53%, a ROC of -47.85% and a ROE of -50.06%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cyclacel Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Cyclacel Pharmaceuticals Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. is Strong Buy (1), with a target price of $20, which is +1 338.85% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclacel Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclacel Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.50, ATR14 : 0.12, CCI20 : 152.43, Chaikin Money Flow : -0.02, MACD : -0.05, Money Flow Index : 56.17, ROC : 13.11, RSI : 51.68, STOCH (14,3) : 82.50, STOCH RSI : 0.93, UO : 57.81, Williams %R : -17.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. in the last 12-months were: Samuel L. Barker (Buy at a value of $5 000), Spiro Rombotis (Buy at a value of $18 000)